1.
L'etude clinique du mois. L'etude ADOPT: quel antidiabetique oral initier chez le patient diabetique de type 2? ; ADOPT study: which first-line glucose-lowering oral medication in...
2.
3.
4.
Evaluation du premier Plan National Nutrition Santé Belge (PNNS-B1)
5.
6.
7.
8.
L'amélioration de l'environnement nutritionnel à l'école
Adult final height after GH therapy for irradiation-induced GH deficiency in childhood survivors of brain tumors: the Belgian experience.
9.
Le medicament du mois. Bydureon: premier agoniste des recepteurs du GLP-1 en une injection hebdomadaire (exenatide a liberation prolongee). ; Bydureon: first once weekly GLP-1 rece...
Pituitary disease in MEN type 1 (MEN1): Data from the France-Belgium MEN1 multicenter study
La sitagliptine dans le traitement du diabete de type 2: le point, cinq ans apres sa commercialisation. ; Sitagliptin in the treatment of type 2 diabetes: insights five years after...
The impact of reimbursement criteria on the appropriateness of 'statin' prescribing.
Le medicament du mois. Rosuvastatine (Crestor). ; Drug of the month. Rosuvastatin (Crestor)
The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients.